NICE (UK) recommends Trodelvy to treat triple negative breast cancer.
NICE (National Institute for Health and Care Excellence (UK)recommended Trodelvy (also called sacituzumab govitecan and made by Gilead Sciences) for treating locally advanced or metastatic triple negative breast cancer which cannot be removed surgically.
It is used after people have had two or more lines of systemic therapies, at least one of them for locally advanced or metastatic disease which can’t be removed surgically.
Triple negative breast cancer can be more aggressive than other types of breast cancer and accounts for a quarter of all deaths from breast cancer despite accounting for only 1 in 5 cases. Because triple-negative breast cancer is not sensitive to hormone therapy or molecular targeted therapy, the usual treatment is chemotherapy.
Trodelvy works by targeting the activity of Trop-2 proteins that are present at high levels on the surface of tumour cells. By targeting Trop-2 it delivers the anti-cancer component of the drug directly to tumour cells, preventing them from multiplying and eventually causing them to die.
The clinical trial evidence shows that Trodelvy increases how long people have before their disease gets worse by around 3 months and how long they live by around 5 months compared with chemotherapy. It is estimated that around 650 people with advanced triple negative breast cancer are eligible for treatment with Trodelvy.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.